Skip to main content

Table 1 Description of the study population

From: Improved survival among colon cancer patients with increased differentially expressed pathways

  

Total population

Group A 1

Group B

  

n

%

n

%

n

%

Sex

Male

94

53.7

18

48.6

14

34.1

 

Female

81

46.3

19

51.4

27

65.9

Center

Kaiser

106

60.6

22

59.5

23

56.1

 

Utah

69

39.4

15

40.5

18

43.9

Site

Proximal

78

47.9

16

45.7

21

53.8

 

Distal

85

52.2

19

54.3

18

46.2

Vital status

Alive

104

59.4

15

40.5

24

58.5

 

CRC death

39

22.3

22

59.5

17

41.5

 

Other death

17

9.7

    
 

Unknown

15

8.6

    

AJCC stage

1

40

23.0

6

16.2

8

19.5

 

2

56

32.2

9

24.3

14

34.1

 

3

57

32.8

15

40.5

9

22.0

 

4

21

12.1

7

18.9

10

24.4

TP53

Non-mutated

98

56.0

22

59.5

26

63.4

 

Mutated

77

44.0

15

40.5

15

36.6

KRAS

Non-mutated

127

72.6

26

70.3

31

75.6

 

Mutated

48

27.4

11

29.7

10

24.4

MSI

Stable

143

81.7

30

81.1

33

80.5

 

Unstable

32

18.3

7

18.9

8

19.5

CIMP

Low

130

74.3

27

73.0

27

65.9

 

High

45

25.7

10

27.0

14

34.1

  

Mean

STD

Mean

STD

Mean

STD

Age

 

65.2

10.2

64.8

10.9

63.2

11.3

  1. 1Groups A and B were randomly selected to determine differentially expressed genes for further analysis.
  2. AJCC, American Joint Committee on Cancer; CIMP, CpG island methylator phenotype; MSI, Microsatellite instability; STD, Standard deviation.